CNBC Stock Blog
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- 10 Stock Picks for This 'Gradual Recovery'
- Recovery's Real Shape? Not a W: Stock Picker
- Market Direction into 2010 Depends on This: Analysts
- Prep Your Portfolio for Next Week: Stock Pickers
- Art Cashin: Why Markets Face 'Enormous' 1-Day Swings
- India or China: Which Is the Better Place to Invest?
- What Traders Expect From This Bank Stock
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
MOST SHARED
- U.S. May Wind Up Green With Envy
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Taking a Page from Obama's Asia Agenda in Investing
- EADS Cautious on Full-Year Forecast after Earnings Dip
- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Sustainability Indices Sprouting Up
- The Cost of Thanksgiving Dinner 2009
- Thai Economy to Grow up to 3.5% in 2010: Prime Minister
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Washington Not Trying to Contain China: Obama
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Quiz: How Much Do You Know About Green?
- Citi Rejects Terra Firma's Latest Bid to Save EMI: Report
- JP Morgan to Bid Over $3 Billion for Cazenove Stake
- Buffett: I Haven't Bought AMEX Shares in Years
- Bristol-Myers to Spin Off Mead Johnson Stock
- BlackRock: Central Banks To Be Net Buyers of Gold
RSS FEED
Text Size 
CNBC News Associate
Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Recommendations:
Allos Therapeutics [ALTH
Loading...
()
]—The company has a positive last trial for treating T-cell lymphoma, bladder cancer and lung cancer. “People may be treated in the real world by the end of this year,” Monane told CNBC.
Medarex [MEDX
Loading...
()
]—The company is in its late stage programs in testing melanoma, a tough-to-treat cancer. They also have solid partnerships with Bristol-Myers [BMY
Loading...
()
], Merck [MRK
Loading...
()
] and Johnson & Johnson [JNJ
Loading...
()
].
Cubist Pharmaceuticals [CBST
Loading...
()
]
Vertex Pharmaceuticals [VRTX
Loading...
()
]—They are in their last phase in developing a treatment for Hepatitis C.
Disclosure:
No immediate information was available for Monane or his firm.
______________________________
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes